VYNE - Why Vyne Therapeutics Stock Is Climbing | Benzinga
Vyne Therapeutics Inc. (NASDAQ: VYNE) shares are trading higher Monday after the company announced a private placement of $88 million and positive data from its Phase 1b trial.
The Details:
In addition to the $88 million private placement, Vyne Therapeutics also announced new preclinical data showing the positive effect of its oral small molecule BD2-selective BET inhibitor, VYN202, in preclinical models of psoriasis and rheumatoid arthritis.
"We are proud to partner with ...